Order relative to authorizing the joint committee on Health Care Financing to make an investigation and study of a certain current Senate documents relative to establish a celiac disease screening pilot program.

194th Legislature (2025-2026)

The bill authorizes a formal study by the Health Care Financing Committee to evaluate the feasibility and design of a celiac disease screening pilot in Massachusetts.

Discharged to the committee on Senate Rules

Summary of Bill: S. 3124 (Massachusetts, 194th General Court)

Purpose and Intent

Authorizes a formal investigation and study by the Joint Committee on Health Care Financing into a current Senate document (Senate Document 2928) that relates to establishing a celiac disease screening pilot program.

The overarching aim is to examine the feasibility, design, and potential implementation of a pilot program to screen for celiac disease within the Commonwealth.

Key Provisions and Provisions Implied by the Order

The bill itself is an order directing the Health Care Financing Committee to investigate and study Senate Document 2928.

The investigation would consider establishing a celiac disease screening pilot program, focusing on how such a program could operate within Massachusetts’ health care system.

The order authorizes the committee to gather information, review existing data or models, solicit expert input, and assess the potential benefits, costs, and logistics of a pilot program.

It does not itself create a program or allocate funds; rather, it initiates a formal review process that could inform future legislation or appropriations.

Who/What Would Be Affected

Persons potentially affected: residents of Massachusetts who may be screened for celiac disease under a pilot program, as well as healthcare providers, insurers, and public health entities involved in screening, diagnosis, and follow-up care.

Governmental entities: the Massachusetts General Court, specifically the Joint Committee on Health Care Financing, and related health policy and regulatory bodies that would be involved in any pilot design, oversight, and potential implementation.

Stakeholders: clinicians, laboratories, patient advocacy groups for celiac disease, payers (public and private), and hospital/clinic systems that would participate in screening and data collection.

Procedural and Timeline Aspects

The bill is an order from the Senate directing the Health Care Financing Committee to conduct an investigation and study regarding Senate Document 2928.

Reported by the Health Care Financing Committee (June 15, 2026) and referred to the Rules of the two branches (June 15, 2026), then discharged to the Senate Rules Committee (June 18, 2026).

The order does not specify a fixed timeline for completion of the study; procedural steps will follow the Rules committee’s handling and any subsequent joint or concurrent actions.

Practical Implications

This is a preliminary step toward evaluating a celiac disease screening pilot, potentially laying groundwork for future legislation, funding decisions, regulatory considerations, and pilot design.

Any actual implementation, funding, eligibility criteria, screening methods (e.g., serology, confirmatory testing), and privacy/data considerations would be developed later as part of the study’s findings and recommendations.

If you’d like, I can add a brief comparison to typical pilot program structures for disease screening or outline potential milestones the committee might consider in their study.